TCWM
BCRX icon

Total Clarity Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Total Clarity Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400
Closed -$4K – 287
2022
Q2 		$4K Buy
+400
New +$4.13K ﹤0.01% 833

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Total Clarity Wealth Management's BCRX Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 400 shares — an estimated $4K sold.

Total Clarity Wealth Management first reported a position in BCRX in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Total Clarity Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Total Clarity Wealth Management sold 400 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $4K.
  • Total Clarity Wealth Management first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Total Clarity Wealth Management's BioCryst Pharmaceuticals position peaked at $4K in Q2 2022.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.